<DOC>
	<DOCNO>NCT02173262</DOCNO>
	<brief_summary>The Integrated Consent Model increasingly use internationally improve patient care . In feasibility study explore whether model feasible practice ; whether use increase number physicians patient take part clinical trial , address critical issue around optimal febrile neutropenia prevention randomize eligible patient either G-CSF ciprofloxacin .</brief_summary>
	<brief_title>REaCT Integrated Consent Model Compare Two Standard Care Regimens</brief_title>
	<detailed_description />
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<criteria>Histologically confirm primary breast cancer Planned TC chemotherapy ≥19 year age Able provide verbal consent Willing complete survey • Contraindication either Ciprofloxacin GCSF</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Breast</keyword>
</DOC>